.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AX07_Ibrexafungerp.Ibrexafungerp .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AX07_Ibrexafungerp.Ibrexafungerp| name: | Ibrexafungerp | |
| ATC code: | J02AX07 | route: | oral |
| compartments: | 2 | |
| dosage: | 300 | mg |
| volume of distribution: | 600 | L |
| clearance: | 25 | L/h |
| other parameters in model implementation | ||
Ibrexafungerp is a novel triterpenoid antifungal agent, approved for the treatment of vulvovaginal candidiasis (VVC) and is under investigation for other serious fungal infections. It has activity against a wide spectrum of Candida species, including strains resistant to azoles and echinocandins. Ibrexafungerp is orally administered and is the first-in-class oral glucan synthase inhibitor, representing a new option for antifungal therapy.
Pharmacokinetics in healthy adult subjects following oral administration.
Spec, A, et al., & Pappas, PG (2019). MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. The Journal of antimicrobial chemotherapy 74(10) 3056–3062. DOI:10.1093/jac/dkz277 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31304536